Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Drug therapy offers substantial cost savings than angioplasty

Many patients with diabetes should forego angioplasties for heart disease and just take medicine instead, according to a new National Institutes of Health study led by Stanford University School of Medicine researcher Mark Hlatky, MD.

18 Nov 2009

Abbott and BG Medicine announce a development and commercialization agreement for galectin-3 biomarker

Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.

17 Nov 2009

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented today at the American Heart Association’s Scientific Sessions.

17 Nov 2009

Aterovax presents results of its sPLA2 activity test in the PEACE trial

Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.

17 Nov 2009

deCODE genetics files voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code

deCODE genetics, Inc. (Nasdaq: DCGN) today announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware to facilitate the sale of substantially all of its assets. deCODE is continuing to operate its business and manage its properties as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code.

17 Nov 2009

Studies reveal link between parental monitoring and decreased marijuana usage in adolescents

Marijuana is the most widely used illicit drug by adolescents, with almost 42% of high school seniors admitting to having experimented with it. Continued marijuana use may result in a number of serious consequences including depression, cognitive impairment, cardiovascular disease, and certain forms of cancer.

17 Nov 2009

Genzyme receives FDA complete response letter for its Lumizyme marketing application

Genzyme Corporation announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease. In its letter, the agency stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are required before the Lumizyme application can be approved.

17 Nov 2009

EKG may not always be correct

The electrical measurements on the electrocardiogram can often mislead physicians in diagnosing the heart condition left ventricular hypertrophy, causing other screening tests to be ordered before a definitive conclusion can be made, according to a Henry Ford Hospital study.

17 Nov 2009

Antioxidant found in vegetables can protect cells from damage caused by infection and injury

Scientists at the University of Pennsylvania School of Medicine discovered that a dietary antioxidant found in such vegetables as broccoli and cauliflower protects cells from damage caused by chemicals generated during the body's inflammatory response to infection and injury. The finding has implications for such inflammation-based disorders as cystic fibrosis (CF), diabetes, heart disease, and neurodegeneration.

17 Nov 2009

ARCA biopharma provides financial and Gencaro NDA update

ARCA biopharma, Inc. today announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for ARCA’s New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Following receipt of the CRL, the Company and the FDA have held a series of meetings to discuss how best to address the requirements identified in the CRL.

17 Nov 2009

Stem cell therapy to treat heart, lung and vascular diseases show positive results

A Florida cardiologist is using stem cell therapy to treat patients who suffer from a range of heart, lung and vascular illnesses. The results have been extraordinary.

16 Nov 2009

Lotus Pharmaceuticals reports $5.4 million net earnings for third-quarter 2009

Lotus Pharmaceuticals, Inc. a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today reported third-quarter 2009 net earnings were $5.4 million, or $0.11 per diluted share, compared with $3.2 million, or $0.07 per diluted share, in 2008. Net revenues were $14.5 million during the third quarter of 2009, compared with $16.7 million in the third quarter of 2008.

16 Nov 2009

Transcendental Meditation lowers rates of heart attack, stroke, and death

Patients with coronary heart disease who practiced the stress-reducing Transcendental Meditation® technique had nearly 50 percent lower rates of heart attack, stroke, and death compared to nonmeditating controls, according to the results of a first-ever study presented during the annual meeting of the American Heart Association in Orlando, Fla., on Nov.16, 2009.

16 Nov 2009

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

16 Nov 2009

Effect of niacin or ezetimibe added to chronic statin therapy on carotid intima media thickness: Study

In combination with statins, adding a medication that raises high-density lipoprotein (HDL) cholesterol was more effective in reversing artery wall plaque buildup and in reducing heart disease risk than adding a drug that lowers low-density lipoprotein (LDL) cholesterol, researchers reported today at the American Heart Association Scientific Sessions 2009.

16 Nov 2009

Effects of vitamin D deficiency amplified by lower levels of sex hormone estrogen

Researchers at Johns Hopkins are reporting what is believed to be the first conclusive evidence in men that the long-term ill effects of vitamin D deficiency are amplified by lower levels of the key sex hormone estrogen, but not testosterone.

16 Nov 2009

Merck to market and develop cardiovascular medicines for a range of cardiovascular disorders

Following the completion of its merger with Schering-Plough, Merck today confirms and underscores its commitment to marketing and developing cardiovascular medicines for a range of cardiovascular disorders.

16 Nov 2009

Study confirms that people with severe mental disorders more at risk of dying from heart disease

A large new study confirms that people with severe mental disorders — such as schizophrenia or other psychotic disorders — are 25 percent to 40 percent more prone to die from heart disease than people without mental illness are.

13 Nov 2009

Decreased heart functions associated with fat collection in different body locations: Study

Researchers from Boston University School of Medicine (BUSM) have shown that fat collection in different body locations, such as around the heart and the aorta and within the liver, are associated with certain decreased heart functions. The study, which appears on-line in Obesity, also found that measuring a person's body mass index (BMI) does not reliably predict the amount of undesired fat in and around these vital organs.

13 Nov 2009

Easy and affordable genetic test from Pathway Genomics

Pathway Genomics™ (www.PATHWAY.com), a privately held, venture-backed company, today announced an exclusive agreement to partner with OptumHealthSM Allies and offer the organization’s 15 million members a 20% discount on Pathway’s Health and Ancestry genetic test.

13 Nov 2009

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Drug therapy offers substantial cost savings than angioplasty

Abbott and BG Medicine announce a development and commercialization agreement for galectin-3 biomarker

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

Aterovax presents results of its sPLA2 activity test in the PEACE trial

deCODE genetics files voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code

Studies reveal link between parental monitoring and decreased marijuana usage in adolescents

Genzyme receives FDA complete response letter for its Lumizyme marketing application

EKG may not always be correct

Antioxidant found in vegetables can protect cells from damage caused by infection and injury

ARCA biopharma provides financial and Gencaro NDA update

Stem cell therapy to treat heart, lung and vascular diseases show positive results

Lotus Pharmaceuticals reports $5.4 million net earnings for third-quarter 2009

Transcendental Meditation lowers rates of heart attack, stroke, and death

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Effect of niacin or ezetimibe added to chronic statin therapy on carotid intima media thickness: Study

Effects of vitamin D deficiency amplified by lower levels of sex hormone estrogen

Merck to market and develop cardiovascular medicines for a range of cardiovascular disorders

Study confirms that people with severe mental disorders more at risk of dying from heart disease

Decreased heart functions associated with fat collection in different body locations: Study

Easy and affordable genetic test from Pathway Genomics

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in